<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GRANISETRON HYDROCHLORIDE- granisetron hydrochloride tablet, film coated </strong><br>Teva Pharmaceuticals USA Inc<br></p></div>
<h1><span class="Bold">GRANISETRON HYDROCHLORIDE TABLETS USP<br>7485<br>Rx only</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_00a798fe-fd7d-417b-9e94-b562f2ccd99d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Granisetron hydrochloride tablets USP contain granisetron hydrochloride, an antinauseant and antiemetic agent. Chemically it is <span class="Italics">endo</span>-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride.</p>
<div class="Figure">
<a name="id324"></a><img alt="granisetron structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02dc4c34-04e8-4f16-8109-b04d600a9c61&amp;name=image-01.jpg">
</div>
<p>                                            C<span class="Sub">18</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O•HCl      M.W. 348.9 (312.4 free base)</p>
<p>Granisetron hydrochloride is a white to off-white crystalline powder that is freely soluble in water and slightly soluble in methanol.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_477f3878-1ac1-4a94-8cda-57efd4c6234f"></a><a name="section-1.1"></a><p></p>
<h2>Tablets for Oral Administration</h2>
<p class="First">Each white to off-white, film-coated, capsule-shaped, granisetron hydrochloride tablet USP contains 1.12 mg granisetron hydrochloride equivalent to granisetron, 1 mg. Inactive ingredients are: hypromellose, lactose monohydrate, macrogol, magnesium stearate, microcrystalline cellulose, polysorbate 80, sodium starch glycolate, and titanium dioxide.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_ee97f4c8-9cc9-407e-92f9-66a7db0d65ac"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Granisetron is a selective 5-hydroxytryptamine<span class="Sub">3</span> (5-HT<span class="Sub">3</span>) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT<span class="Sub">1</span>; 5-HT<span class="Sub">1A</span>; 5-HT<span class="Sub">1B/C</span>; 5-HT<span class="Sub">2</span>; for alpha<span class="Sub">1-</span>, alpha<span class="Sub">2-</span>, or beta-adrenoreceptors; for dopamine-D<span class="Sub">2</span>; or for histamine-H<span class="Sub">1</span>; benzodiazepine; picrotoxin or opioid receptors.</p>
<p>Serotonin receptors of the 5-HT<span class="Sub">3</span> type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT<span class="Sub">3</span> receptors. This evokes vagal afferent discharge, inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Animal studies demonstrate that, in binding to 5-HT<span class="Sub">3</span> receptors, granisetron blocks serotonin stimulation and subsequent <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> due to high-dose cisplatin or arrested <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> within 5 to 30 seconds.</p>
<p>In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.</p>
<p>Following single and multiple oral doses, granisetron hydrochloride tablets slowed colonic transit in normal volunteers. However, granisetron hydrochloride had no effect on oro-cecal transit time in normal volunteers when given as a single intravenous (IV) infusion of 50 mcg/kg or 200 mcg/kg.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9e2ea872-139a-467f-bd3e-67c9544a2889"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In healthy volunteers and adult cancer patients undergoing chemotherapy, administration of granisetron hydrochloride tablets produced mean pharmacokinetic data shown in <span class="Bold">Table 1</span>.</p>
<a name="_RefID27868B8D4D8C42DC958D9920A95AEE2A"></a><table width="100%">
<caption><span>Table 1. Pharmacokinetic Parameters (Median [range]) Following Granisetron Hydrochloride Tablets </span></caption>
<col width="17%">
<col width="24%">
<col width="21%">
<col width="20%">
<col width="17%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Not determined after oral administration; following a single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Peak Plasma Concentration (ng/mL)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Terminal Phase Plasma Half-Life (h)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Volume of Distribution (L/kg)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Total Clearance (L/h/kg)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Cancer Patients </span><br>1 mg bid, <br>7 days (n = 27)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5.99 [0.63 to 30.9]</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N.D.<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">N.D.</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.52 [0.09 to 7.37]</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">Volunteers </span><br>single 1 mg dose (n = 39)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.63 [0.27 to 9.14]</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6.23 [0.96 to 19.9]</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.94 [1.89 to 39.4]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.41 [0.11 to 24.6]</p></td>
</tr>
</tbody>
</table>
<p>N.D. Not determined.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_609bf3a0-4137-4336-933b-5c62b4851bab"></a><a name="section-2.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">When granisetron tablets were administered with food, AUC was decreased by 5% and C<span class="Sub">max</span> increased by 30% in non-fasted healthy volunteers who received a single dose of 10 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60ca403b-73b0-4cef-8905-55a10441279d"></a><a name="section-2.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e479de63-a580-458e-a3ac-e15ef3bcbc98"></a><a name="section-2.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Granisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation. <span class="Italics">In vitro</span> liver microsomal studies show that granisetron’s major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P-450 3A subfamily. Animal studies suggest that some of the metabolites may also have 5-HT<span class="Sub">3</span> receptor antagonist activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ee8fef0-c31d-4b8b-b561-fca80bbe2196"></a><a name="section-2.1.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">Clearance is predominantly by hepatic metabolism. In normal volunteers, approximately 11% of the orally administered dose is eliminated unchanged in the urine in 48 hours. The remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_de42b70b-1ca2-4b22-aee8-41d595f7dc9d"></a><a name="section-2.1.5"></a><p></p>
<h3>Subpopulations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2bda6c5-afd3-4495-b2fc-f3f10a2469a7"></a><a name="section-2.1.5.1"></a><p></p>
<h4>Gender</h4>
<p class="First">The effects of gender on the pharmacokinetics of granisetron hydrochloride tablets have not been studied. However, after intravenous infusion of granisetron hydrochloride, no difference in mean AUC was found between males and females, although males had a higher C<span class="Sub">max</span> generally.</p>
<p>In elderly and pediatric patients and in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the pharmacokinetics of granisetron was determined following administration of intravenous granisetron.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df9f280f-4eb9-4231-bf5f-0034fdad1e65"></a><a name="section-2.1.5.2"></a><p></p>
<h4>Elderly</h4>
<p class="First">The ranges of the pharmacokinetic parameters in elderly volunteers (mean age 71 years), given a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection, were generally similar to those in younger healthy volunteers; mean values were lower for clearance and longer for half-life in the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e0d7f26-2bf9-438d-8c9a-a712f8e610f8"></a><a name="section-2.1.5.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> patients</h4>
<p class="First">Total clearance of granisetron was not affected in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> who received a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_455178e1-e4a6-4df8-beca-7e7c46dd3aca"></a><a name="section-2.1.5.4"></a><p></p>
<h4>Hepatically impaired patients</h4>
<p class="First">A pharmacokinetic study with intravenous granisetron hydrochloride in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> due to neoplastic liver involvement showed that total clearance was approximately halved compared to patients without <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Given the wide variability in pharmacokinetic parameters noted in patients, dosage adjustment in patients with hepatic functional impairment is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ad97d47-5f7e-4bbd-9746-d0b4ae7dc963"></a><a name="section-2.1.5.5"></a><p></p>
<h4>Pediatric patients</h4>
<p class="First">A pharmacokinetic study in pediatric cancer patients (2 to 16 years of age), given a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection, showed that volume of distribution and total clearance increased with age. No relationship with age was observed for peak plasma concentration or terminal phase plasma half-life. When volume of distribution and total clearance are adjusted for body weight, the pharmacokinetics of granisetron are similar in pediatric and adult cancer patients.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_96de29e6-a018-47b6-8501-8ea946a182fe"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_666b7025-5a11-4e9e-937e-4177d7b5ee23"></a><a name="section-3.1"></a><p></p>
<h2>Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">Granisetron hydrochloride tablets prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer therapy, as shown by 24 hour efficacy data from studies using both moderately- and highly-emetogenic chemotherapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d822eee-c984-448e-8cc3-d8838bc13c36"></a><a name="section-3.1.1"></a><p></p>
<h3>Moderately Emetogenic Chemotherapy</h3>
<p class="First">The first trial compared granisetron hydrochloride tablet doses of 0.25 mg to 2 mg twice a day, in 930 cancer patients receiving, principally, cyclophosphamide, carboplatin, and cisplatin (20 mg/m<span class="Sup">2</span> to 50 mg/m<span class="Sup">2</span>). Efficacy was based on complete response (i.e., no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, no rescue medication), no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <span class="Bold">Table 2</span> summarizes the results of this study.</p>
<a name="_RefID43ABDD825CDC4805AA894C6211BB21B4"></a><table width="100%">
<caption><span>Table 2. Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> 24 Hours Post-Chemotherapy<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col width="17%">
<col width="22%">
<col width="21%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Chemotherapy included oral and injectable cyclophosphamide, carboplatin, cisplatin (20 mg/m<span class="Sup">2</span> to 50 mg/m<span class="Sup">2</span>), dacarbazine, doxorubicin, epirubicin.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, no rescue medication.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>Statistically significant (P &lt; 0.01) vs. 0.25 mg bid.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>Statistically significant (P &lt; 0.01) vs. 0.5 mg bid.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Percentages of Patients </span><br><span class="Bold">Granisetron Hydrochloride Tablet Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Efficacy Measures</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">0.25 mg twice a day (n = 229) %</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">0.5 mg twice a day (n = 235) %</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">1 mg twice a day (n = 233) %</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">2 mg twice a day (n = 233) %</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Complete Response<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">61</p></td>
<td class="Botrule Lrule" align="center"><p class="First">70<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">81<a href="#footnote-4" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">72<a href="#footnote-4" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">66</p></td>
<td class="Botrule Lrule" align="center"><p class="First">77<a href="#footnote-4" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">88<a href="#footnote-4" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">79<a href="#footnote-4" class="Sup">‡</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">48</p></td>
<td class="Botrule Lrule" align="center"><p class="First">57</p></td>
<td class="Botrule Lrule" align="center"><p class="First">63<a href="#footnote-4" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">54</p></td>
</tr>
</tbody>
</table>
<p>Results from a second double-blind, randomized trial evaluating granisetron hydrochloride tablets 2 mg once a day and granisetron hydrochloride tablets 1 mg twice a day were compared to prochlorperazine 10 mg twice a day derived from a historical control. At 24 hours, there was no statistically significant difference in efficacy between the two granisetron hydrochloride tablet regimens. Both regimens were statistically superior to the prochlorperazine control regimen (see <span class="Bold">Table 3</span>).</p>
<a name="_RefIDAF26ACC454AC41218DA313C846D5EEF2"></a><table width="100%">
<caption><span>Table 3. Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> 24 Hours Post-Chemotherapy<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<col width="14%">
<col width="29%">
<col width="29%">
<col width="28%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Moderately emetogenic chemotherapeutic agents included cisplatin (20 mg/m<span class="Sup">2</span> to 50 mg/m<span class="Sup">2</span>), oral and intravenous cyclophosphamide, carboplatin, dacarbazine, doxorubicin.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Historical control from a previous double-blind granisetron hydrochloride trial.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, no rescue medication.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Statistically significant (P &lt; 0.05) vs. prochlorperazine historical control.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, no rescue medication.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Percentages of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Efficacy Measures</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Granisetron Hydrochloride Tablets 1 mg twice a day (n = 354) %</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Granisetron Hydrochloride Tablets 2 mg once a day (n = 343) %</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Prochlorperazine</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a><span class="Bold"> 10 mg twice daily (n = 111) %</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Complete Response<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">69<a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">64<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">82<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">77<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">48</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">51<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">53<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Total Control<a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">51<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">50<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">33</p></td>
</tr>
</tbody>
</table>
<p>Results from a granisetron hydrochloride tablets 2 mg daily alone treatment arm in a third double-blind, randomized trial, were compared to prochlorperazine (PCPZ), 10 mg bid, derived from a historical control. The 24 hour results for granisetron hydrochloride tablets 2 mg daily were statistically superior to PCPZ for all efficacy parameters: complete response (58%), no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (79%), no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (51%), total control (49%). The PCPZ rates are shown in <span class="Bold">Table 3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4304259b-b99f-4299-ba5a-0b27011d840a"></a><a name="section-3.1.2"></a><p></p>
<h3>Cisplatin-Based Chemotherapy</h3>
<p class="First">The first double-blind trial compared granisetron hydrochloride tablets 1 mg bid, relative to placebo (historical control), in 119 cancer patients receiving high-dose cisplatin (mean dose 80 mg/m<span class="Sup">2</span>). At 24 hours, granisetron hydrochloride tablets 1 mg bid was significantly (P&lt; 0.001) superior to placebo (historical control) in all efficacy parameters: complete response (52%), no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (56%), and no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (45%). The placebo rates were 7%, 14%, and 7%, respectively, for the three efficacy parameters.</p>
<p>Results from a granisetron hydrochloride tablets 2 mg once a day alone treatment arm in a second double-blind, randomized trial, were compared to both granisetron hydrochloride tablets 1 mg twice a day and placebo historical controls. The 24 hour results for granisetron hydrochloride tablets 2 mg once a day were: complete response (44%), no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (58%), no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (46%), total control (40%). The efficacy of granisetron hydrochloride tablets 2 mg once a day was comparable to granisetron hydrochloride tablets 1 mg twice a day and statistically superior to placebo. The placebo rates were 7%, 14%, 7%, and 7%, respectively, for the four parameters.</p>
<p>No controlled study comparing granisetron injection with the oral formulation to prevent chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b3acf9f-e120-45e4-8a0a-28e3ef01afc4"></a><a name="section-3.2"></a><p></p>
<h2>Radiation-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d55e5a7c-c894-4aa4-a7d0-5c0c7feefc67"></a><a name="section-3.2.1"></a><p></p>
<h3>Total Body Irradiation</h3>
<p class="First">In a double-blind randomized study, 18 patients receiving granisetron hydrochloride tablets, 2 mg daily, experienced significantly greater antiemetic protection compared to patients in a historical negative control group who received conventional (non-5-HT<span class="Sub">3</span> antagonist) antiemetics. Total body irradiation consisted of 11 fractions of 120 cGy administered over 4 days, with three fractions on each of the first 3 days, and two fractions on the fourth day. Granisetron hydrochloride tablets were given one hour before the first radiation fraction of each day.</p>
<p>Twenty-two percent (22%) of patients treated with granisetron hydrochloride tablets did not experience <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or receive rescue antiemetics over the entire 4 day dosing period, compared to 0% of patients in the historical negative control group (P&lt; 0.01).</p>
<p>In addition, patients who received granisetron hydrochloride tablets also experienced significantly fewer emetic episodes during the first day of radiation and over the 4 day treatment period, compared to patients in the historical negative control group. The median time to the first emetic episode was 36 hours for patients who received granisetron hydrochloride tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5656e0b2-593a-4f35-913d-6486831917f1"></a><a name="section-3.2.2"></a><p></p>
<h3>Fractionated Abdominal Radiation</h3>
<p class="First">The efficacy of granisetron hydrochloride tablets, 2 mg daily, was evaluated in a double-blind, placebo-controlled randomized trial of 260 patients. Granisetron hydrochloride tablets were given 1 hour before radiation, composed of up to 20 daily fractions of 180 to 300 cGy each. The exceptions were patients with seminoma or those receiving whole abdomen irradiation who initially received 150 cGy per fraction. Radiation was administered to the upper abdomen with a field size of at least 100 cm<span class="Sup">2</span>.</p>
<p>The proportion of patients without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and those without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> for granisetron hydrochloride tablets, compared to placebo, was statistically significant (P&lt; 0.0001) at 24 hours after radiation, irrespective of the radiation dose. Granisetron hydrochloride was superior to placebo in patients receiving up to 10 daily fractions of radiation, but was not superior to placebo in patients receiving 20 fractions.</p>
<p>Patients treated with granisetron hydrochloride tablets (n = 134) had a significantly longer time to the first episode of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (35 days vs. 9 days, P&lt; 0.001) relative to those patients who received placebo (n = 126), and a significantly longer time to the first episode of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11 days vs. 1 day, P&lt; 0.001). Granisetron hydrochloride provided significantly greater protection from <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> than placebo.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_39bd9990-25dc-408f-94b2-1b50c15ae09f"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Granisetron hydrochloride tablets USP are indicated for the prevention of:</p>
<dl>
<dt>1.</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.</dd>
<dt>2.</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with radiation, including total body irradiation and fractionated abdominal radiation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_167bd5eb-1de0-437c-b52e-c6184a30217b"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Granisetron hydrochloride tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_9b2232c0-8cf3-4349-aaff-ec93c50fef3f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4d5c508a-783c-431a-97e2-1b35f9e2e278"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span><br>The development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with 5-HT<span class="Sub">3</span> receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).  Some of the reported cases were fatal.   <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> occurring with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of another 5-HT3 receptor antagoinist alone has also been reported.  The majority of reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> related to 5-HT<span class="Sub">3</span> receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.  <br>Symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include the following combination of signs and symptoms: <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).  Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially with concomitant use of granisetron and other serotonergic drugs. If symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occur, discontinue granisetron and initiate supportive treatment. Patients should be informed of the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially if granisetron is used concomitantly with other serotonergic drugs (see <span class="Bold">Drug Interactions</span>).</h2>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8d9cbc5b-ec2e-4389-93a9-a4047aa88fe7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Granisetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of granisetron in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and/or gastric <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.</p>
<p>An adequate QT assessment has not been conducted, but QT prolongation has been reported with granisetron hydrochloride. Therefore, granisetron hydrochloride should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_1b74a49c-27e3-467d-ab41-e77aa033edce"></a><a name="section-7.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system <span class="Italics">in vitro</span>. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics, and anti-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> medications commonly prescribed with antiemetic treatments. Granisetron hydrochloride injection also does not appear to interact with emetogenic cancer chemotherapies. Because granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of granisetron. No specific interaction studies have been conducted in anesthetized patients. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by granisetron <span class="Italics">in vitro.</span></p>
<p>In <span class="Italics">in vitro</span> human microsomal studies, ketoconazole inhibited ring oxidation of granisetron. However, the clinical significance of <span class="Italics">in vivo</span> <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with ketoconazole is not known. In a human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in a 25% increase in total plasma clearance of intravenous granisetron. The clinical significance of this change is not known.</p>
<p>QT prolongation has been reported with granisetron hydrochloride. Use of granisetron hydrochloride in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic, this may result in clinical consequences.</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (including altered mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) (see <span class="Bold">WARNINGS</span>)<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_09cb76d7-7b00-4368-bdf1-34f1ae3135c5"></a><a name="section-7.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 24 month carcinogenicity study, rats were treated orally with granisetron 1, 5 or 50 mg/kg/ day (6, 30 or 300 mg/m<span class="Sup">2</span>/day). The 50 mg/kg/day dose was reduced to 25 mg/kg/day (150 mg/m<span class="Sup">2</span>/day) during week 59 due to toxicity. For a 50 kg person of average height (1.46 m<span class="Sup">2</span> body surface area), these doses represent 4, 20, and 101 times the recommended clinical dose (1.48 mg/m<span class="Sup">2</span>, oral) on a body surface area basis. There was a statistically significant increase in the incidence of hepatocellular carcinomas and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males treated with 5 mg/kg/day (30 mg/m<span class="Sup">2</span>/day, 20 times the recommended human dose based on body surface area) and above, and in females treated with 25 mg/kg/day (150 mg/m<span class="Sup">2</span>/day, 101 times the recommended human dose based on body surface area). No increase in <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> was observed at a dose of 1 mg/kg/day (6 mg/m<span class="Sup">2</span>/day, 4 times the recommended human dose based on body surface area) in males and 5 mg/kg/day (30 mg/m<span class="Sup">2</span>/day, 20 times the recommended human dose based on body surface area) in females. In a 12 month oral toxicity study, treatment with granisetron 100 mg/kg/day (600 mg/m<span class="Sup">2</span>/day, 405 times the recommended human dose based on body surface area) produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> in male and female rats while no such tumors were found in the control rats. A 24 month mouse carcinogenicity study of granisetron did not show a statistically significant increase in tumor incidence, but the study was not conclusive.</p>
<p>Because of the tumor findings in rat studies, granisetron hydrochloride should be prescribed only at the dose and for the indication recommended (see <span class="Bold">INDICATIONS AND USAGE</span> and <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
<p>Granisetron was not mutagenic in <span class="Italics">in vitro</span> Ames test and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation assay, and <span class="Italics">in vivo</span> mouse micronucleus test and <span class="Italics">in vitro</span> and <span class="Italics">ex vivo</span> rat hepatocyte UDS assays. It, however, produced a significant increase in UDS in HeLa cells <span class="Italics">in vitro</span> and a significant increased incidence of cells with polyploidy in an <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration test.</p>
<p>Granisetron at oral doses up to 100 mg/kg/day (600 mg/m<span class="Sup">2</span>/day, 405 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_4b4be6ae-dca0-49da-aa66-ba46884972bc"></a><a name="section-7.3"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_bb09eb32-4f01-4eee-b259-005433f24e69"></a><a name="section-7.3.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17db25b4-fc33-45dc-ab17-81849ebc599f"></a><a name="section-7.3.1.1"></a><p></p>
<h4>Pregnancy category B</h4>
<p class="First">Reproduction studies have been performed in pregnant rats at oral doses up to 125 mg/kg/day (750 mg/m<span class="Sup">2</span>/day, 507 times the recommended human dose based on body surface area) and pregnant rabbits at oral doses up to 32 mg/kg/day (378 mg/m<span class="Sup">2</span>/day, 255 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f2304ca1-8cb6-4fe8-8e1c-0ce805e1ec09"></a><a name="section-7.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether granisetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_07811831-c6a1-4e5c-bb78-42d09c88b3a6"></a><a name="section-7.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_b38ee5e2-d9ad-49bd-a737-acfb129ee5ca"></a><a name="section-7.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">During clinical trials, 325 patients 65 years of age or older received granisetron hydrochloride tablets; 298 were 65 to 74 years of age, and 27 were 75 years of age or older. Efficacy and safety were maintained with increasing age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_9db29c9e-569c-4ec5-a022-b95f5e548f37"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">QT prolongation has been reported with granisetron hydrochloride (see <span class="Bold">PRECAUTIONS</span> and <span class="Bold">Drug Interactions</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34cde959-908f-4484-bebb-55345d0b165e"></a><a name="section-8.1"></a><p></p>
<h2>Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">Over 3700 patients have received granisetron hydrochloride tablets in clinical trials with emetogenic cancer therapies consisting primarily of cyclophosphamide or cisplatin regimens.</p>
<p>In patients receiving granisetron hydrochloride tablets 1 mg bid for 1, 7 or 14 days, or 2 mg daily for 1 day, adverse experiences reported in more than 5% of the patients with comparator and placebo incidences are listed in <span class="Bold">Table 4</span>.</p>
<a name="_RefID58B20ACBFC124057B5773C04357DD4A8"></a><table width="100%">
<caption><span>Table 4. Principal Adverse Events in Clinical Trials </span></caption>
<col width="15%">
<col width="27%">
<col width="27%">
<col width="19%">
<col width="12%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Adverse events were recorded for 7 days when granisetron hydrochloride tablets were given on a single day and for up to 28 days when granisetron hydrochloride tablets were administered for 7 or 14 days.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Metoclopramide/dexamethasone; phenothiazines/dexamethasone; dexamethasone alone; prochlorperazine.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>Usually mild to moderate in severity.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Percent of Patients With Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Granisetron Hydrochloride Tablets</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a><span class="Bold">1 mg twice a day (n = 978)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Granisetron Hydrochloride Tablets</span><a href="#footnote-11" class="Sup">*</a><span class="Bold">2 mg once a day (n = 1450)</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a><span class="Bold">(n = 599)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Placebo (n = 185)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">21%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">13%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">18%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">14%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">14%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
</tbody>
</table>
<p>Other adverse events reported in clinical trials were:</p>
<p><span class="Italics">Gastrointestinal:</span> In single-day dosing studies in which adverse events were collected for 7 days, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (20%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (12%) were recorded as adverse events after the 24 hour efficacy assessment period.</p>
<p><span class="Italics">Hepatic:</span> In comparative trials, elevation of AST and ALT (&gt; 2 times the upper limit of normal) following the administration of granisetron hydrochloride tablets occurred in 5% and 6% of patients, respectively. These frequencies were not significantly different from those seen with comparators (AST: 2%; ALT: 9%).</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (1%); <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been observed rarely.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (5%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (5%), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1%). One case compatible with, but not diagnostic of, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> has been reported in a patient treated with granisetron hydrochloride tablets.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span>Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes severe (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) have been reported.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (5%). Events often associated with chemotherapy also have been reported: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (9%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (6%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (4%), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (3%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (2%).</p>
<p>Over 5000 patients have received injectable granisetron hydrochloride in clinical trials.</p>
<p><span class="Bold">Table 5</span> gives the comparative frequencies of the five commonly reported adverse events (≥ 3%) in patients receiving granisetron hydrochloride injection, 40 mcg/kg, in single-day chemotherapy trials. These patients received chemotherapy, primarily cisplatin, and intravenous fluids during the 24 hour period following granisetron hydrochloride injection administration.</p>
<a name="_RefID0A3E0BE71B2A4EF883E84B5B4528E012"></a><table width="100%">
<caption><span>Table 5. Principal Adverse Events in Clinical Trials—Single-Day Chemotherapy </span></caption>
<col width="14%">
<col width="60%">
<col width="24%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Adverse events were generally recorded over 7 days post-granisetron hydrochloride injection administration.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Metoclopramide/dexamethasone and phenothiazines/dexamethasone.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Percent of Patients with Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Granisetron Hydrochloride Injection</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a><span class="Bold">40 mcg/kg (n = 1268)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a><span class="Bold">(n = 422)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p>In the absence of a placebo group, there is uncertainty as to how many of these events should be attributed to granisetron hydrochloride, except for <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, which was clearly more frequent than in comparison groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c1980c2-5062-40b9-b23e-d133801c4591"></a><a name="section-8.2"></a><p></p>
<h2>Radiation-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">In controlled clinical trials, the adverse events reported by patients receiving granisetron hydrochloride tablets and concurrent radiation were similar to those reported by patients receiving granisetron hydrochloride tablets prior to chemotherapy. The most frequently reported adverse events were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, however, was less prevalent in this patient population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d19bffd5-42b9-4702-a4ca-97a66411fc34"></a><a name="section-8.3"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">QT prolongation has been reported with granisetron hydrochloride (see <span class="Bold">PRECAUTIONS</span> and <span class="Bold">Drug Interactions</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a943e984-2d41-48fb-b524-6f9f4058e309"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no specific treatment for granisetron hydrochloride overdosage. In case of overdosage, symptomatic treatment should be given. Overdosage of up to 38.5 mg of granisetron hydrochloride injection has been reported without symptoms or only the occurrence of a slight <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8e61f482-6ee9-4a69-b38d-488de5639dc6"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13ff90cd-6440-4550-bef6-7b562e59850e"></a><a name="section-10.1"></a><p></p>
<h2>Emetogenic Chemotherapy</h2>
<p class="First">The recommended adult dosage of oral granisetron hydrochloride tablets USP is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to 1 hour before chemotherapy, and the second tablet, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd6d9826-baf4-4a19-a092-64af4a942954"></a><a name="section-10.1.1"></a><p></p>
<h3>Use in the Elderly, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span> Patients or Hepatically Impaired Patients</h3>
<p class="First">No dosage adjustment is recommended (see <span class="Bold">CLINICAL PHARMACOLOGY</span>, <span class="Bold">Pharmacokinetics</span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_5985a624-de67-4422-b357-55ec43e400fe"></a><a name="section-10.1.2"></a><p></p>
<h3>Pediatric Use</h3>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8a811ed-1a80-41f8-a549-5762e3145c24"></a><a name="section-10.2"></a><p></p>
<h2>Radiation (Either Total Body Irradiation or Fractionated Abdominal Radiation)</h2>
<p class="First">The recommended adult dosage of oral granisetron hydrochloride tablets USP is 2 mg once daily. Two 1 mg tablets are taken within 1 hour of radiation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5023f5a9-0643-4998-b7f7-a27438ad8e4d"></a><a name="section-10.2.1"></a><p></p>
<h3>Pediatric Use</h3>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4fcc6fd2-d475-4fb2-af0a-920c070c6a72"></a><a name="section-10.2.2"></a><p></p>
<h3>Use in the Elderly</h3>
<p class="First">No dosage adjustment is recommended.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2f08641a-8762-49c7-9c6c-a80a9547cbbf"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Granisetron hydrochloride tablets USP are available as:</p>
<p>1 mg, white to off-white, film-coated, capsule-shaped tablet, debossed with the number “93? on one side and “7485? on the other. They are available in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 2 (1 card of 2 unit dose tablets) and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 20 (4 cards of 5 unit dose tablets each).</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container closed tightly. Protect from light.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_13567f9c-e567-4d9f-908d-6fb44d2e9aa2"></a><a name="section-12"></a><p></p>
<h1>PATIENT COUNSELING INFORMATION<br>Advise patients of the possibility of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of granisetron and another serotonergic agent such as medications to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. Advise patients to seek immediate medical attention if the following symptoms occur: changes in mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, neuromuscular symptoms with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>.</h1>
<p class="First">Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. E 8/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c80a2751-aab2-4361-8190-2c7bb4dc9736"></a><a name="section-13"></a><p></p>
<h1>Package/Label Display Panel, Part 1 of 2</h1>
<div class="Figure">
<a name="id-735964599"></a><img alt="Granisetron Hydrochloride Tablets USP 1 mg, 2s Box, Part 1 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02dc4c34-04e8-4f16-8109-b04d600a9c61&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_cef78e29-5c85-4781-b1ab-2a0305614411"></a><a name="section-14"></a><p></p>
<h1>Package/Label Display Panel, Part 2 of 2</h1>
<div class="Figure">
<a name="id-735964597"></a><img alt="Granisetron Hydrochloride Tablets USP 1 mg, 2s Box, Part 2 of 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02dc4c34-04e8-4f16-8109-b04d600a9c61&amp;name=image-04.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4fcde9cb-f364-4b50-b1a3-04fe6d2cc339"></a><a name="section-14.1"></a><p></p>
<h2>Granisetron Hydrochloride Tablets USP 1 mg, 2s Box Text</h2>
<p class="First"><span class="Bold">NDC</span> 0093-<span class="Bold">7485</span>-12</p>
<p><span class="Bold">GRANISETRON HYDROCHLORIDE Tablets USP</span></p>
<p><span class="Bold">1 mg*</span></p>
<p>*Each tablet contains granisetron hydrochloride, USP equivalent to 1 mg of granisetron.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">2 Tablets (1 x 2) – Unit of Use</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables"><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRANISETRON HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">granisetron hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-7485</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GRANISETRON HYDROCHLORIDE</strong> (GRANISETRON) </td>
<td class="formItem">GRANISETRON</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">93;7485</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-7485-12</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem">01/02/2008</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-7485-19</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-7485-20</td>
<td class="formItem">20  in 1 BOX</td>
<td class="formItem">01/02/2008</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-7485-19</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><img alt="Image of Product" style="width:100%;" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02dc4c34-04e8-4f16-8109-b04d600a9c61&amp;name="></td></tr>
</tbody></table></div>
</body></html>
